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Abstract
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and degenerative
disease of the central nervous system (CNS). While etiology of the disease remains
unknown, genetic susceptibility and autoimmune mechanisms in the initiation and
progression of the disease have been strongly suggested. Experimental autoimmune
encephalomyelitis (EAE) is commonly used to study immune regulation of MS. Infiltration
by CD4+ T cells, through blood-brain barrier (BBB), precedes the onset and relapses
of MS. CNS migration and homing patterns of T cells are tightly synchronized by
astrocyte and microglia derived cytokines and chemokines. Autoimmune, CNS antigenreactive, infiltrating T cells produce and locally release cytokines including but not
limited to IFNγ, IL-2, IL-6, IL-16, IL-17, TNFa, and chemokines including CCL2, CCL5
and CXCL10. Chemokine mediated chemotaxis is exclusive for activated cell state
and most chemokines do not discriminate between distinct cell types. Conversely, a
cytokine IL-16 is a CD4-specific cytokine-ligand and exclusively induces chemotaxis
of CD4+T cells, by binding and signaling through CD4, regardless of T cell activation
state. In this article we focus on CD4+ T cell-mediated autoimmune responses to CNS
antigens because of their importance for immunopathology of MS and EAE. We focus
on autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) because of
its relevance for immunopathology of MS. We emphasize a role of IL-16 in regulation
of CD4+T cell mediated autoimmune responses to MOG in EAE and MS. While a role
of IL-16 in regulation of other CD4+T cell mediated autoimmune diseases has been
established, its role in regulation of MS remains to be determined. Emerging data from
our laboratories have indicated that IL-16-mediated CD4+ T cell chemoattraction has
a significant role in regulation of CD4+ T cell-mediated autoimmune responses to CNS
antigens. We propose an important function of this cytokine in regulation of relapsingremitting EAE.

T CELL RESPONSES IN CNS AUTOIMMUNITY
Multiple sclerosis (MS) is an immunepathologically-mediated,
putative autoimmune disease. It ranks among the leading causes
of disability in North America. Autoimmune mechanisms of
central nervous system (CNS) damage are primarily mediated by
auto-reactive CD4+ T cells, which are specific for encephalitogenic
epitopes of myelin peptides. Migration of autoimmune T cells
from the periphery into CNS parenchyma leads to inflammation,
demyelination and damage of axons, oligodendrocytes and
neurons [1]. This autoimmune T cell mediated tissue damage

results in impairment of motor function leading to paralysis.
Disease is progressive and often takes a relapsing-remitting
course. Progression and severity of the disease as well as types
of CNS lesions are highly heterogeneous among patients with
MS [2]. In an effort to replicate heterogeneity of clinical course
and CNS lesions observed in MS patients, different types of
experimental models have been developed.
In experimental autoimmune encephalomyelitis (EAE),
an autoimmune model of MS, major effector mechanisms
of autoimmune demyelination in the CNS are mainly, but
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not exclusively, mediated by Th1 helper/inducer CD4+
encephalitogenic T cells [3], and followed by the phagocytosis
of myelin debris by macrophages. Roles for cytotoxic CD8+ T
cell, B cell and NK cell mediated regulation of immune response
to myelin antigens have been proposed [4,5]. B cell-mediated
mechanisms are of particular interest as auto-antibodies to
myelin oligodendrocyte glycoprotein (MOG) play a significant
role in regulation of CNS demyelination, especially in pediatric
MS patients [6].

Development and progression of an autoimmune response
to myelin specific antigens results from a fine balance and
interactions between the effector and regulatory T cells (Treg)
in the periphery [7]. Once activated and clonally expanded, autoaggressive myelin antigen-specific CD4+ effector T cells, Th1,
Th17 and Th9 coordinate CNS inflammation and induce tissue
damage. Conversely, regulatory T cells (Treg) and Th2 CD4+ T
cells have roles in controlling and downregulating effector T cell
mediated inflammation. CD4+ T cell infiltration into CNS precedes
onset of clinical signs of disease. Similarly, relapses of disease are
based upon the reappearance of activated CD4+ T effector cells
into the CNS, which subsequently leads to demyelination and
axonal damage [8]. Transmigration of encephalitogenic CD4+ T
cells through the blood-brain barrier (BBB) is a process tightly
regulated by the production of chemoattractant chemokines
and expression of their cognate receptors by both, glial and
inflammatory cells [9]. Timing and levels of produced chemokines
and their corresponding cognate receptors are primarily
regulated by cytokines, produced by activated mononuclear cells
and glia [10]. These chemokines and their cognate receptors
associated with MS include: CCL2 (MCP-1) /CCR2, CCL3 (MIP1α) /CCR1/CCR5, CCL4 (MIP-1β) /CCR5 and CCL5 (RANTES) /
CCR1/CCR3/CCR5 [11,12]. Similar to MS, a role for chemokines
in regulation of macrophage and activated CD4+ T cell migration
has been documented in different models of EAE [13,14].

T CELL RESPONSES TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) IN RELAPSING- REMITTING EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE)

Immune regulation of EAE relapses is not completely
understood. Contribution of local microenvironment in
immunomodulation of encephalitogenic cell responses remains
in the focus of investigation. We originally demonstrated
presence of encephalitogenic cells and revealed their trafficking
patterns and distribution throughout the entire course (389 days
– 10 relapses) of relapsing-remitting EAE in SJL Thy-1 congenic
mice. We analyzed homing of T cells to the CNS throughout the
course of relapsing-remitting EAE. The SJL-Thy1a mouse strain
was derived by crossing SJL (Thy1b) and AKR (Thy1a) mice and
by twelve subsequent successive backcrosses of SJL to select
breeders expressing the Thy1.1 phenotype [15] . EAE was induced
by adoptive transfer of sensitized and in vitro restimulated
myelin basic protein (MBP) -specific lymph node cells from SJL
(Thy1.2+) mice into SJL-Thya (Thy1.1+) congenic hosts. In CNS of
SJL-Thy 1a recipients, we observed donor Thy 1.2+ cells in small
infiltrates disseminated throughout the white matter, beginning
prior the onset of clinical signs. Seven days post cell transfer,
Thy1.2+ donor cells constituted 2.5% of the infiltrating cells
J Immunol Clin Res 1: 1006 (2013)

and reached peak value of approximately 10% during the first
attack. This five-fold increase in numbers of Thy1.2+ donor cells
raises the question of intrinsic mechanisms driving either local or
peripheral expansion of Thy 1.2+ cells [16,17].

Understanding the regulation of CD4+ T cell infiltration in
response to MOG35-55 is of great importance for MS [18]. Studies
of immunoregulatory mechanisms underlying heterogeneity of
MS lesions [2] and clinical course require use of different EAE
models, which closely replicate heterogeneous immunopathology
of the human disease. Development of appropriate models is the
major challenge in enhancing MS related research [19,20]. Strong
immune responses to MOG35-55 by CD4+ Th1 cells are found in
patients with MS. The encephalitogenic epitope of myelin
oligodendrocyte glycoprotein (MOG) p35-55 is highly conserved
among species, including mouse and human. In EAE, CD4+ T cell
immune responses to MOG35-55 are restricted by MHC class II (H2b) expression. Following immunization with MOG35-55, most B6
(H-2b) mice fully recover after the acute disease, with one or no
relapse, or develop chronic sustained disease [21] . Studies of
mechanisms regulating relapsing disease in response to MOG35-55
have been hampered by the lack of appropriate animal models.
Our laboratory originally described relapsing-remitting EAE
model in (B6 x SJL) F1 (H-2b/s) mice [22], which compared to B6
(H-2b) non-relapsing model, shares great similarity with clinical
course and histopathology of human MS. We observed a profound
depletion of myelin associated glycoprotein (MAG), concomitant
with depletion of axonal neurofilament (NF160), and sharp
elevations of PARPp85, which is a 85 kD caspase cleaved fragment
of a DNA binding enzyme, poly (ADP-ribose) polymerase (PARP)
and whose presence indicate irreversible apoptosis, occurring
exclusively in relapsing H-2b/s mice. Our data implicate genetic
factors as main regulators of preferential myelin-associated
glycoprotein (MAG) depletion and axonal damage in (B6 x SJL)
F1 (H-2b/s) mice with MOG35-55 induced EAE [23]. An excessive
loss of MAG, believed to result from a distal oligodendrogliopathy
is observed in the subtype III of MS lesions [2]. Similar to our
observations in EAE model, a recent study in neuromyelitis
optica reports histopathology of demyelinating lesions with
preferential decrease of MAG and oligodendrocyte apoptosis
[24]. We propose that MOG-induced EAE in (B6 x SJL) F1 (H-2b/s)
mice may serve as a useful animal model in studying mechanisms,
which govern autoimmune-induced preferential loss of MAG, and
its impact on oligodendroglial pathology. Therefore, a specific
contribution of SJL background in (B6 x SJL) F1 (H-2b/s) mice
have a potential to modulate an H-2b restricted immune response
to encephalitogenic epitope. This specific immune modulation
leads to distinct clinical EAE, immunopathology of relapsing
lesions and T cell responses to MOG35-55. H-2b/s mice developed
consistently more severe relapsing remitting disease, compared
to H-2b mice, which develop less severe non-relapsing disease.
In relapsing H-2b/s mice, we observed extensive demyelination
and small inflammatory infiltrates scattered throughout the
white matter. Infiltrating cell phenotypes in CNS lesions were
skewed towards CD4+ T cells and B220+ B cells with fewer Mac-3+
macrophages. To investigate mechanisms underlying preferential
accumulation of CD4+ T cells and B220+ B cells over macrophages
in relapsing lesions of H-2b/s mice, we analyzed a macrophage
chemoattractant protein (CCL2, MCP-1) chemokine and its
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corresponding receptor CCR2 expression throughout disease
in H-2b/s and H-2b mice. We noted less abundant levels of CCL2
message in acute and relapsing lesions of H-2b/s mice compared to
H-2b. Conversly, CCR2 levels did not differ significantly between
the strains in acute and relapsing disease. Surprisingly, a switch
of CCL2 positive immunostaimig from GFAP+ astrocytes, which
are considered a main CCL2 producing cell in EAE, to a CD3+ T
cells, was observed. By two-color immunostaining, we further
identified CD3+CD4+ T cells as major sources of CCL2 production
in relapsing lesions of H-2b/s mice. Our data point to existence
of locally derived factors that facilitate intra CNS migration of
CD4+ T cell compared to macrophages during relapsing stages of
disease. We further examined whether the significantly higher
incidence of relapses in H-2b/s rather than H-2b mice might be
the result of either higher numbers of long term memory cells
or their facilitated recall responses to MOG35-55, in the peripheral
lymphoid organs of H-2b/s and H-2b mice. MOG35-55 induced recall
T cell responses were notably higher in H-2b/s mice during the
relapse, suggesting the existence of mechanisms that facilitate
clonal expansion of MOG35-55 specific T cells. We proposed that
this specific enhancement of CD4+ T cells mediated mechanisms
play a major role in relapsing disease in H-2b/s mice.

In a search for factors, which favor local enrichment of
CD4+ T cells, we decided to study IL-16 over other known CD4+
T cell chemoattractant chemokines because IL-16 selectively
chemoattracts CD4+ T cells [25,26]. Also, IL-16 has a potential
to modulate chemokine mediated T cell migration. Reciprocal
desensitization of a chemokine receptor CCR5 and CD4
molecule by IL-16 and chemokine MIP-1, respectively, has been
demonstrated [27]. Chemokines known to regulate inflammation
in EAE through their chemoattractant properties, such as CCL2
(MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES)
are not exclusive for CD4+ T cells. More importantly, these
chemokines regulate migration of activated mononuclear cells,
including CD4+ T cells, which express corresponding chemokine
receptors. Even though IL-16 attracts CD4+ monocytes, only
a fraction of monocyte/macrophages expresses CD4 on their
surface and therefore it was feasible to hypothesize that IL-16mediated chemoattraction would contribute primarily to CD4+ T
cell dominated infiltration. The fact that IL-16 chemoattraction
is not related to CD4+ T cell activation state was especially
interesting because such non-selectivity might provide
recruitment from the pool of long-term Th1 memory (peripheral
memory) cells [28] in our MOG35-55 EAE model [22] which do
not readily express activation markers and activation induced
chemokine receptors. The existence of peripheral memory cells
to MOG35-55 is suggested by our finding of strong lymph node and
splenic T cell proliferation to MOG35-55 in relapsing H-2b/s mice.
While a role of IL-16 in regulation of inflammatory infiltration
in several autoimmune diseases, including rheumatoid arthritis
[29] has been established, there were no data available prior to
our studies on the role of IL-16 in MS and EAE.

ROLE OF IL-16 IN IMMUNE REGULATION OF
AUTOIMMUNE RESPONSES

IL-16 is an exclusive chemoattractant cytokine for CD4+T cells
[30]. IL-16 preferentially induces chemoattraction of CD4+ Th1
J Immunol Clin Res 1: 1006 (2013)

over Th2 cells with a requirement of CCR5 chemokine receptor
[31]. Among other immunomodulatory properties, IL-16 has an
important role in regulation of CD4+ T cell – dendritic cell and T –
B cell communication [32]. Immunotherapy of MS with anti-CD4
antibodies showed beneficial effects in ameliorating severity of
disease by abrogating CD4+ T cell mediated immune responses.
Major pitfalls of such therapy were due to overall T cell depletion
and immune-compromised defense from infection [33,34]. . In
EAE, non-depleting anti-CD4 antibody therapy protected from
disease through induction of peripheral T-cell tolerance to myelin
basic protein (MBP) in PL/J mice [35]. In general antibody-based
therapies face a challenge of the requirement for humanized
antibodies to be successfully used for human. Therapy with
two different types of humanized CD3 antibodies was used in
treatment of autoimmune diabetes type I (T1D). Overall, this
treatment showed beneficial results in ameliorating disease over
two-year period. It was noted that response to treatment was
highly heterogeneous between patients with T1D. Underlying
mechanisms of protection were governed through reduction
of T cell mediated responses and likely through modulation of
regulatory T cell responses [36]. Our laboratory demonstrated
in relapsing (B6 x SJL) F1 (H-2b/s) EAE mice that therapy with
monoclonal anti-IL-16 antibody, administered 24-48 hour after
relapse, reversed paralysis. When such therapy was delayed
beyond 48 - hour period, it did not have an effect in ameliorating
the disease. Our data suggest that success of anti-inflammatory
therapy depends on timing with relapsing episode and that the
opportune therapeutic window is narrow, following shortly
after relapse development. In treated mice, mononuclear cell
infiltration within the white matter was significantly reduced,
while infiltration in the meninges seemed comparable to that in
control, non-treated EAE mice. This pattern of mononuclear cell
infiltrates scattered throughout the white matter is consistent
with our previous findings [22] and is clearly different from
that found in EAE models in other strains of mice, including B6
(H-2b) mice, where large perivascular and meningeal infiltrates
were observed. With quantitative analysis of cell phenotypes, we
demonstrated that anti-IL-16 therapy had most profound effect in
decreasing the numbers of infiltrating CD4+ T cell, where a fivefold
decrease was observed. Therapy exhibited less robust effect on
B cell infiltration, where approximately two-fold decrease was
observed. Therapy with anti-IL-16 antibody did not significantly
reduce numbers of infiltrating Mac3+ macrophages. Overall, antiIL-16 therapy was successful in reducing CD4+ T cell infiltration,
ameliorating severity of established and relapsing disease.
Repeated treatment showed more sustained effect by diminishing
severity and frequency of relapses and enabling longer and more
successful recovery during remission. Treatments with IL-16
neutralizing antibody reduced numbers of infiltrating CD4+ T
cells, in the spinal cord white matter, reduced demyelination
and fostered better preservation of axons in treated mice. Taken
together, our results show an important role of IL-16 in regulation
of CD4+ T cell inflammation, demyelination, axonal degeneration
and progression and severity of relapsing EAE. We described a
novel therapeutic approach to specifically decrease CD4+ T cell
infiltration in EAE based on IL-16 neutralization. Our findings
have high relevance for the development of new therapies for
relapsing EAE and potentially MS [37].
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IL-16 mRNA expression and protein production have been
detected in Th1- and Th2-mediated human and experimental
diseases. We demonstrated increased IL-16 mRNA expression
and protein levels in CNS lesions in EAE and MS [38,39]. We
observed increased levels of IL-16 co-localized with CD4+ T
cells in pancreatic isles of spontaneously diabetic BB/W rats,
with type1 diabetes mellitus (T1D) [40]. In vivo neutralization
studies performed to assess the role of IL-16 in pathogenesis
of T1D, demonstrated that neutralization of IL-16 prevented
nonobese diabetic (NOD) mice from developing the disease
by interfering with recruitment of CD4+ T cell. In NOD mice,
increased production of IL-16 correlated with invasive insulitis.
IL-16 immunoreactivity was observed in infiltrating CD4+ T cells
[41]. We found that elevated levels of IL-16 along with increase
in active caspase-3 and CD4 levels correlated with stages of
clinically active disease in both (B6 x SJL) F1 (H-2b/s) and B6 (H2b) mice. CNS levels of bioactive IL-16 were notably higher in
H-2b/s compare with H-2b mice at all stages, being most prominent
during relapse. We observed similar patterns of regulation for
IL-16 and active caspase-3 in peripheral lymphoid organs and
in T cells isolated from lymph nodes following T-cell activation
in vitro. We co-immunoprecipitated IL-16 with CD4 from CNS of
relapsing H-2b/s mice. Our data suggest that caspse-3 mediated
production of IL-16 by infiltrating CD4+ T cells, contributes to
ongoing neuroinflammation by chemoattraction of additional
waves of CD4+ T cells [38]. In MS lesions, analyzed from postmortem snap frozen tissue, we made the original observation
of markedly increased levels of pro- and secreted IL-16 (80 kD
and 22 kD, respectively) compared with control. IL-16 levels
were highest in acute, diminished in subacute and peaked
again in chronic active lesions. Compared to lesions, lower but
still appreciable IL-16 levels were found in normal-appearing
white matter adjacent to active lesions. We further found that
increased levels of IL-16 corresponded to increase in active
caspase-3, T-bet and phosphorylated Stat-1. We co-localzed
IL-16 immunoreactivity to CD3+, Tbet+ and active caspase-3+
mononuclear cells. We further observed the correlation between
increased levels of secreted IL-16, CD4+ Th1 cell inflammation,
and phosphorylation of axonal neurofilament (medium and
heavy chain) [NF (M+H) ], in MS lesions. All together, our data
suggest that IL-16 production occurs in MS lesions. Our data
indicate a role for IL-16 in regulation of CD4+ Th1 inflammation
and subsequent changes in the axonal cytoskeleton in MS lesions
[39].

CONCLUSIONS

Role of CD4+T cells in regulation of relapsing disease is
not completely understood. IL-16 is a specific cytokine-ligand
for CD4, which chemoattracts exclusively CD4+ T cells. Other
biological properties of IL-16 important for regulation of
autoimmune responses to CNS antigens include regulation of:
CD25 expression by CD4+ T cells; T cell-dendritic cell, and T cell-B
cell communication; chemokine production and modulation of
chemokine-mediated chemotaxis. IL-16 has an important role in
regulation of CD4+ T cell infiltration in MOG35-55 induced relapsingremitting EAE in (B6 x SJL) F1 (H-2b/s) mice. Encephalitogenic
epitope (p35-55) of myelin oligodendrocyte protein (MOG) is
highly conserved among species, including mice and humans.
Relapsing-remitting EAE model in (B6 x SJL) F1 (H-2b/s) mice
J Immunol Clin Res 1: 1006 (2013)

resembles closely human pathohistology and clinical course of
relapsing MS. The model of relapsing-remitting EAE in (B6 x SJL)
F1 mice provides a good choice to study effects of single gene
deficiencies on relapsing phenotype, as most gene disruptions
were done in B6 mice.
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